Vomiting with Luvox (Fluvoxamine)
Vomiting occurs in approximately 5% or more of patients taking Luvox and is common enough that it causes 2% of patients to discontinue the medication. 1
Incidence and Clinical Significance
According to the FDA drug label, vomiting is classified as one of the most commonly observed adverse reactions that is likely drug-related, with an incidence of 5% or greater and at least twice that of placebo 1. This places vomiting among the top tier of side effects alongside nausea, somnolence, insomnia, and other common reactions.
Key Clinical Points:
- Discontinuation rate: Vomiting leads to treatment discontinuation in 2% of patients treated with fluvoxamine 1
- Nausea and vomiting combined are the most common reasons for stopping the medication in clinical trials 2
- The incidence appears consistent across both OCD and depression treatment populations 1
Context Among SSRIs
While fluvoxamine shares the gastrointestinal side effect profile common to all SSRIs, guideline evidence notes that venlafaxine has a higher incidence of nausea and vomiting than other SSRIs 2. Fluvoxamine falls within the typical SSRI range but is notably associated with a higher incidence of nausea and vomiting compared to tricyclic antidepressants 3.
Real-world safety data from 24,624 patients showed that nausea occurred in 15.7% of patients, with vomiting being among the principal reasons for premature discontinuation 4.
Clinical Management Considerations
- Timing: Gastrointestinal symptoms like vomiting typically occur early in treatment
- Monitoring: The FDA label recommends assessing adverse effects within 1-2 weeks of initiation 2
- Overdose context: In overdose situations, vomiting is one of the commonly observed symptoms and is generally benign 1, 5
Common Pitfall to Avoid:
Do not dismiss early gastrointestinal complaints as they are a leading cause of treatment discontinuation. Address these symptoms proactively with dose titration strategies or symptomatic management to improve medication adherence.